TABLE 1.
Demographics and baseline characteristics
| Baseline characteristics | Survey phase (n=1004) | Treatment phase (n=313) |
|---|---|---|
| Age, years | 47.6±17.3 | 46.1±17.2 |
| Sex, n (%) | ||
| Male | 364 (36.3) | 114 (36.4) |
| Female | 640 (63.7) | 199 (63.6) |
| Duration of asthma diagnosis, months | 162.3±147.6 | 162.6±139.0 |
| Duration of allergic rhinitis diagnosis, months | – | 131.4±135.4 |
| Primary trigger for asthma exacerbation, n (%) | ||
| Viral infection | – | 89 (28.4) |
| Pet dander | – | 40 (12.8) |
| Dust mites | – | 35 (11.2) |
| Weather conditions/humidity | – | 34 (10.9) |
| Pollen | – | 30 (9.6) |
| Smoking history, n (%) | ||
| Patient smokes | – | 56 (17.9) |
| Member of household smokes | – | 55 (17.6) |
| Patient quit smoking | – | 88 (28.1) |
| Member of household quit smoking | – | 44 (14.1) |
| Medical history, n (%) | ||
| Allergic rhinitis | – | 313 (100.0) |
| Sinusitis | – | 91 (29.1) |
| Obesity | – | 107 (34.2) |
| Eczema | – | 65 (20.8) |
| ICS drug group, n (%) | ||
| Missing | – | 6 (1.9) |
| ICS only | – | 154 (49.2) |
| Fluticasone propionate | – | 103 (32.9) |
| Budesonide | – | 28 (8.9) |
| Beclomethasone dipropionate | – | 12 (3.8) |
| Ciclesonide | – | 11 (3.5) |
| ICS/LABA | – | 153 (48.9) |
| Budesonide + formoterol fumarate | – | 78 (24.9) |
| Fluticasone propionate + salmeterol xinafoate | – | 74 (23.6) |
| Ciclesonide + formoterol fumarate | – | 1 (0.3) |
Data presented as mean ± SD unless otherwise specified. ICS Inhaled corticosteroid; LABA Long-acting beta-2-agonist